prr very much alive says matt lehman, page-11

Isn't Martin questioning the efficacy of CVac here;
"Lehman says the studies show that CVac is working well to increase T-cell activity, and to get them to the cancer site, but it is struggling with the most complex area preventing, or blocking, the cancer's own defences."

But he wants to partner with someone who can add value? Right? Is there a complimentary treatment that can overcome the CVac deficiencies? If so it makes sense to change strategy but as Loosingcash says cost and timelines blow out. The Board need to make a big decision now. Those few with medical experience will be in the hot seat.

Birdseye - based on your assumption long term holders now at 3.5%.